MedPage Today on MSN2 天
IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for ...
Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a Phase I clinical trial ...
Pharmabiz1 天
Vividion Therapeutics doses first patient in phase I study of RAS-PI3Ka inhibitor to treat ...
San Diego, California Friday, April 4, 2025, 16:00 Hrs [IST] ...
Medical Dialogues1 天
Bayer AG arm Vividion Therapeutics doses first patient in Phase I study of RAS-PI3Kα ...
Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...
Vividion Therapeutics, Inc.: Vividion Therapeutics Doses First Patient in Phase I Study of ...
VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...